Search

Displaying results 651 - 660 of 10000 in total
  1. Target

    Actin-related protein 2/3 complex subunit 1B

    go.drugbank.com/bio_entities/BE0004249
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:11741539, PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:11741539, PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 1BSynonyms: Arp2/3 complex 41 kDa subunit
  2. Target

    Actin-related protein 2/3 complex subunit 3

    go.drugbank.com/bio_entities/BE0004253
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 3Synonyms: Arp2/3 complex 21 kDa subunit
  3. Target

    ATP synthase F(0) complex subunit g, mitochondrial

    go.drugbank.com/bio_entities/BE0009022
    TargetHumans

    Part of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(0) complex subunit g, mitochondrial
  4. Indication

    B Vitamin Deficiency

    go.drugbank.com/conditions/DBCOND0067035
    Drugs: Flavin mononucleotide · Hydroxocobalamin · Riboflavin · Saw palmetto
    Synonyms: Vitamin B complex deficiency, B-complex deficiency NOS
  5. Drug

    Tetracycline

    go.drugbank.com/drugs/DB00759
    ApprovedInvestigationalVet approvedWithdrawn

    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.

    Products: PIPERACILLINA E TAZOBACTAM EG, COMTREX JARABE
  6. Drug

    Betamethasone

    go.drugbank.com/drugs/DB00443
    ApprovedInvestigationalVet approved

    Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states inclu...

    Mixtures: GENTAMICINA E BETAMETASONE EG, GENTAMICINA E BETAMETASONE IDIProducts: BETAMETASONE EG, BETAMETASONE EG STADA
  7. Drug

    PF-04937319

    go.drugbank.com/drugs/DB15009
    Investigational

    PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).

  8. Drug

    Verapamil

    go.drugbank.com/drugs/DB00661
    ApprovedInvestigational

    into therapy in the early 1960s. … Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced

    International brands: Verogalid ERMixtures: Trandolapril and Verapamil Hydrochloride ER, Trandolapril and Verapamil Hydrochloride ER
  9. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    compare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to

  10. Drug

    Dextromethorphan

    go.drugbank.com/drugs/DB00514
    ApprovedInvestigational

    [A215412] Although similar in structure to other opioids, it has minimal interaction with opioid receptors.[A215412] Dextromethorphan was granted FDA approval before 3 December 1957.

    Mixtures: COUGH - EN PLUS, COUGH-EN LINCTUSCategories: Uncompetitive N-methyl-D-aspartate Receptor Antagonist